Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.

@article{Panaccione2004CanadianAO,
  title={Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.},
  author={Remo Panaccione and Richard N Fedorak and Guy Aumais and Charles N. Bernstein and Alain Bitton and Kenneth Croitoru and Robert A Enns and Brian G. Feagan and Martin Fishman and Gordon R. Greenberg and Anne M. Griffiths and John K. Marshall and Imran Rasul and Daniel C. Sadowski and Ernest G. Seidman and Hillary A. Steinhart and Lloyd R. Sutherland and Eric Walli and Gary Wild and C. Noel Williams and Mary Zachos},
  journal={Canadian journal of gastroenterology = Journal canadien de gastroenterologie},
  year={2004},
  volume={18 8},
  pages={
          503-8
        }
}
Remo Panaccione MD (Co-Chair)1, Richard N Fedorak MD (Co-Chair)2, Guy Aumais MD3, Charles N Bernstein MD4, Alain Bitton MD5, Ken Croitoru MD6, Robert Enns MD7, Brian Feagan MD8, Marty Fishman MD7*, Gordon Greenberg MD9, Anne Griffiths MD9, John K Marshall MD6*, Imran Rasul MD10*, Daniel Sadowski MD2*, Ernest Seidman MD11, Hillary Steinhart MD9, Lloyd Sutherland MD1, Eric Walli MD12*, Gary Wild MD5, C Noel Williams MD2, Mary Zachos MD9 
2 Citations

Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons, and The American Society of Colorectal Surgeons: Evidence-Based Reviews in Surgery – Colorectal Surgery

The Canadian Association of General Surgeons and the American College of Surgeons jointly sponsor a program entitled “Evidence Based Reviews in Surgery” (EBRS), supported by an educational grant from Ethicon Inc and Ethicon Endo Surgery Inc.

Mortality Trends in Crohn's Disease and Ulcerative Colitis: A Population-based Study in Québec, Canada

All-cause mortality was significantly higher in CD and UC populations than in the general population, however, a decreasing trend with time was observed in all-cause and some cause-specific SMRs.

References

SHOWING 1-10 OF 60 REFERENCES

Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.

  • R. Fedorak
  • Medicine
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • 2001
These guidelines are presented as a follow-up to the original Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of infliximab in Crohn's disease, and have been updated to reflect knowledge gained from two pivotal randomized clinical trails.

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.

© Queen's Printer and Controller of HMSO 2003HTA reports may be freef "×b Y‰ýaeT€s®:| I¾V>c%;i¥‹|¶¼eU|Þeio°aÂ9a¾¦0¹A[ayâ?;ðueiA Ks7”EIAoIýUI²V;I—v

Safety and Steroid-Sparing Experience Using Infliximab for Crohn's Disease at a Pediatric Inflammatory Bowel Disease Center

Infliximab is safe and effective for treating pediatric patients with CD and a steroid-sparing effect was demonstrated, which suggests utility in the treatment of refractory disease.

Infliximab and Crohn's QOL

Although the authors considered the haematological, renal, hepatic and bone mineral side-effects of 5-aminosalicylates, thiopurines, methotrexate and corticosteroids, they did not consider pancreatic sideeffects.

Infliximab (REMICADE) Therapy in the Treatment of Pediatric Crohn's Disease

The results of this trial suggest that infliximab may be safe and effective as short-term therapy of medically refractory moderate to severe CD in a pediatric population.

Infliximab in Crohn's disease: first anniversary clinical experience

Clinical experience with infliximab closely parallels the results of the controlled clinical trials, and includes steroid-sparing effects.

Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta.

The patient group in the present study realized significant clinical benefit, with minimal adverse effects, following treatment with infliximab, and clinical response rates paralleled those previously described in placebo controlled trials and retrospective clinical practice reviews.

Clinical experience with infliximab therapy in 100 patients with Crohn's disease

The authors' clinical response rates mirror the efficacy reported in the controlled trials for active and fistulous disease and steroid-sparing efficacy was seen in 40% of steroid-dependent patients.

Drug side‐effects in IBD

Although the authors considered the haematological, renal, hepatic and bone mineral side-effects of 5-aminosalicylates, thiopurines, methotrexate and corticosteroids, they did not consider pancreatic sideeffects.

Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience

Infliximab is an established treatment for steroid‐resistant and fistulating Crohn’s disease. Although efficacy has been shown in clinical trials, financial implications often limit its use and
...